Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results

Journal of Neurosurgery - Tập 89 Số 3 - Trang 425-430 - 1998
Evanthia Galanis1, Jan C. Buckner2, Robert P. Dinapoli, Bernd W. Scheithauer, Robert B. Jenkins, Chiao Hua Wang, Judith R. OʼFallon, Gist H. Farr
1Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
2Medical Oncology

Tóm tắt

Object. Gliosarcoma, a rare malignancy of the central nervous system, consists of gliomatous and sarcomatous elements. There are conflicting reports regarding its aggressiveness and cell line of origin compared with those of glioblastoma multiforme (GBM). The goal of this study was to compare clinicopathological features such as disease-free survival time and actual survival time in patients with gliosarcoma with a matched group of patients with GBM as well as with the entire group of patients with GBM.

Methods. The authors report on 18 cases of gliosarcoma derived from a series of 748 Grade 4 astrocytoma cases that were part of four consecutive randomized Phase III trials conducted between 1979 and 1996. In this series the gliosarcoma group represented only 2.4% of all GBMs and included 11 men and seven women with a median age of 61.5 years (range 31–81 years). The median tumor size was 5 cm (range 2–8 cm). The locations, all supratentorial, included temporal in 44%, parietal in 28%, frontal in 17%, and occipital in 11%. The 18 patients with gliosarcomas, all Grade 4 (World Health Organization classification), were compared with the entire group of 730 patients with GBM and a control group of 18 patients with GBM matched for known prognostic factors including patient age, randomization date, performance status, extent of resection, and protocol number. Patients in all treatment groups received radiation and nitrosourea-based chemotherapy.

The median time to progression and the median survival times for the patients with gliosarcoma were 28.0 and 35.1 weeks as compared with 24.7 and 41.6 weeks for the entire group of patients with GBM (log rank test, p = 0.94 and 0.27, respectively) and 16.7 and 34.4 weeks in the control group (p = 0.20 and 0.84, respectively). In previous molecular cytogenetic analyses of gliosarcoma these authors have shown similar genetic changes in the gliomatous and sarcomatous components.

Conclusions. The data obtained in this study support the conclusion that gliosarcoma shares significant clinical and genetic similarities with GBM and that the same principles should be applied for patient enrollment in research protocols and treatment for these two kinds of tumor.

Từ khóa


Tài liệu tham khảo

Barnard RO, 1987, Acta Neuropathol, 69, 23, 10.1007/BF00687034

Biernat W, 1995, J Neuropathol Exp Neurol, 54, 651, 10.1097/00005072-199509000-00006

Boerman RH, 1996, J Neuropathol Exp Neurol, 55, 973, 10.1097/00005072-199609000-00004

Buckner JC, 1997, Proc Am Soc Clin Oncol, 16, 385a

Burger PC, 1994, Atlas of Tumor Pathology

Cerame MA, 1985, Neurosurgery, 17, 413, 10.1227/00006123-198509000-00003

Conill C, 1990, Cancer, 65, 1864, 10.1002/1097-0142(19900415)65:8<1864::AID-CNCR2820650832>3.0.CO;2-U

Dinapoli RP, 1993, J Clin Oncol, 11, 1316, 10.1200/JCO.1993.11.7.1316

Elliott TE, 1997, J Neurooncol, 33, 239, 10.1023/A:1005735405986

Feigin I, 1958, Cancer, 11, 264, 10.1002/1097-0142(195803/04)11:2<264::AID-CNCR2820110207>3.0.CO;2-D

10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S

Haddad SF, 1992, J Neuropathol Exp Neurol, 51, 493, 10.1097/00005072-199209000-00003

10.1002/1097-0142(19930801)72:3<850::AID-CNCR2820720334>3.0.CO;2-4

Ho KL, 1990, Acta Neuropathol, 81, 178, 10.1007/BF00334506

James CD, 1988, Cancer Res, 48, 5546

10.1111/j.1365-2990.1991.tb00713.x

10.2307/2281868

10.1111/j.1750-3639.1993.tb00752.x

LeBlanc M, 1992, Biometrics, 48, 411, 10.2307/2532300

10.1002/1097-0142(19910501)67:9<2342::AID-CNCR2820670922>3.0.CO;2-B

10.3171/jns.1976.45.4.0398

Paulus W, 1994, Acta Neuropathol, 88, 420, 10.1007/BF00389493

10.2307/2344317

Richman AV, 1980, J Neuropathol Exp Neurol, 39, 329, 10.1097/00005072-198005000-00007

10.1002/1097-0142(196908)24:2<270::AID-CNCR2820240210>3.0.CO;2-5

Tada T, 1987, Clin Neuropathol, 6, 160

Thông tin
Thông tin xuất bản

Journal of Neurosurgery

Tập 89 Số 3

425-430

Thông tin tác giả